Ultrasound for Detecting Chemotherapy-Induced Peripheral Neuropathy
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the effectiveness of ultrasound in detecting nerve damage caused by the chemotherapy drug oxaliplatin (Eloxatin) in individuals with gastrointestinal cancer. The goal is to determine if ultrasound provides a better diagnosis for nerve problems experienced by some patients during treatment. This trial suits those with gastrointestinal cancer who are receiving or have received oxaliplatin-based chemotherapy and have symptoms of nerve damage, such as tingling or numbness. As an unphased trial, it offers a unique opportunity to contribute to research that could enhance diagnostic methods for nerve damage.
Do I have to stop taking my current medications for this trial?
The protocol does not specify if you need to stop taking your current medications.
What prior data suggests that ultrasound is safe for detecting neuropathy?
Research shows that oxaliplatin, a chemotherapy drug, can cause peripheral neuropathy, a type of nerve damage. This common side effect often results in numbness or tingling, particularly in the hands and feet. Cold temperatures can intensify these sensations for some individuals. This nerve damage may continue to worsen for a few months even after treatment ends.
Studies have found that patients taking oxaliplatin often experience more numbness than those on other treatments. Although nerve damage is a significant concern, patients should know that this side effect is well-documented and closely monitored during treatment.12345Why are researchers excited about this trial?
Researchers are excited about using ultrasound to detect chemotherapy-induced peripheral neuropathy because it offers a non-invasive way to monitor nerve health. Unlike current methods, which often rely on symptom reporting or invasive nerve conduction studies, ultrasound can provide real-time images of peripheral nerves. This technique has the potential to improve early detection and intervention, which could help manage symptoms more effectively and enhance patients' quality of life during chemotherapy.
What evidence suggests that ultrasound is effective for detecting chemotherapy-induced neuropathy?
Research has shown that ultrasound holds promise for spotting nerve damage caused by chemotherapy. In this trial, participants will undergo peripheral nerve ultrasound to detect changes in nerves due to chemotherapy drugs like oxaliplatin. Understanding these nerve changes is crucial for better symptom management. Although some research suggests ultrasound might also help with chemotherapy-related pain, this trial focuses on detection. Overall, ultrasound is proving useful in helping doctors see how chemotherapy affects nerves more clearly.678910
Who Is on the Research Team?
Roy E. Strowd
Principal Investigator
Wake Forest University Health Sciences
Are You a Good Fit for This Trial?
This trial is for patients with any stage of gastrointestinal or colorectal cancer who are currently or have previously been treated with oxaliplatin-based chemotherapy and now show signs of peripheral neuropathy. Participants must be able to understand and sign a consent form.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Ultrasound Assessment
Participants undergo peripheral nerve ultrasound to assess nerve cross-sectional area
Follow-up
Participants are monitored for changes in nerve conduction and neuropathy symptoms
What Are the Treatments Tested in This Trial?
Interventions
- Oxaliplatin
- Ultrasound - Serial and Tibial Nerve
Oxaliplatin is already approved in European Union, United States, Canada, Japan, Switzerland, China for the following indications:
- Colorectal cancer
- Colorectal cancer
- Colorectal cancer
- Colorectal cancer
- Colorectal cancer
- Colorectal cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor
National Cancer Institute (NCI)
Collaborator